



FOR IMMEDIATE RELEASE

Contacts: Kathy Kregel, 970-221-1301 or Dan Stinchcomb, 970-231-2290

COLORADO INCUBATORS DOUBLE TEAM PROMISING VACCINE STARTUP

Fort Collins, CO__After successfully completing a rigorous selection process, InViragen, LLC has been invited to join both the Fort Collins Technology Incubator and the Fitzsimons BioBusiness Incubator. For the first time in the history of either Incubator, they will be working together to maximize the assistance they provide to the promising Fort Collins startup. InViragen is focused on developing vaccines for new, emerging markets worldwide. Vaccines for dengue fever, West Nile disease and plague will take advantage of new trends in the global vaccine marketplace, including the growing economies of developing countries, new non profit vaccine initiatives, increasing public and governmental awareness of the value of vaccines and the need for vaccines against potential bioweapon threats.

“InViragen represents two firsts for the Fort Collins Technology Incubator. This outstanding startup is the first bioscience firm to enter our program and this will be the first time that we coordinate assistance with the strong bioscience incubator at Fitzsimons. We will focus on our proven professional business services while Fitzsimons will bring a team of talented bioscience mentors to the table. It’s a win-win for all involved!” remarked Fort Collins Incubator director, Kathy Kregel.

“The selection of InViragen by the Fort Collins and Fitzsimons Incubators is a distinct honor and concrete validation that we have a viable business proposition. We are eager to begin working with these two well-respected programs. Together they provide InViragen with a terrific package of services, advice and funding assistance and we are confident that they will significantly increase our probability of success,” said InViragen CEO Dr. Dan Stinchcomb.

The City of Fort Collins, Colorado State University, Colorado State University Research Foundation and the Northern Colorado Economic Development Corporation fund the Fort Collins Technology Incubator.

XXX

ABOUT INVIRAGEN

Over 15 million people worldwide die each year of infectious diseases. Vaccines to prevent these diseases are the most cost effective solutions to improving global health. InViragen is committed to developing vaccines to address this need.

InViragen's lead product is a vaccine to protect against dengue fever, a disease that potentially affects 2.5 billion people in tropical regions throughout the world as well as millions of travelers to those countries. InViragen also is developing a vaccine to protect against West Nile disease which spread throughout the United States and North America since its introduction in the Western Hemisphere in 1999, and a vaccine to protect against plague, a dangerous bioterrorist threat.